In the last decades, lysosomes and mitochondria were considered distinct and physically separated organelles involved in different cellular functions. While lysosomes were thought to exclusively be the rubbish dump of the cell involved in the degradation of proteins and other cell compartments, mitochondria were considered solely involved in the oxidation of energy substrate to get ATP, together with other minor duties. Nowadays, our view of these organelles is profoundly changed since studies demonstrated that mitochondria and lysosome are mutually functional, maintaining proper cell homeostasis. Furthermore, the onset of neurodegenerative diseases (i.e., Parkinson's disease, Alzheimer's disease, lysosomal storage disorders, and amyotrophic lateral
sclerosis) is tightly linked to mutations in mitochondrial and lysosomal regulators. In this context, mitochondrial dysfunction leads to lysosomal impairment and buildup of autophagy by-products, whereas lysosomal imperfections trigger functional and morphological mitochondrial defects. Here, we provide an updated overview covering recent findings about mitochondria and lysosomal interaction in physiology and pathophysiology, focusing the attention on the molecular mechanism that control their interdependence. Keywords: lysosomes, mitochondria, neurodegenerative diseases. J. Neurochem. (2018) 147, 291--309. In the last few years, our understanding of functional interactions of intracellular organelles has significantly grown. Specifically, organelle biology has come to the characterization of interorganelle contacts that physically and functionally link different intracellular structures, like mitochondria and lysosomes. Given their key role in energy metabolism and ATP production, mitochondria are mainly known as the powerhouse of the cell. Beyond this, mitochondria are the primary site of heme synthesis, iron sulfur clusters biosynthetic pathway, apoptosis, calcium homeostasis and many other cellular processes. On the other hand, lysosomes have been much less characterized. In fact, they have been historically thought to be involved only in the degradation of macromolecules through autophagy. Nevertheless, we currently know that they are also important intracellular nutrient sensors, amino acid reservoir and, together with mitochondria, vital regulators of calcium homeostasis (Jewell and Guan 2013; Yuan et al. 2013; Raffaello et al. 2016) .
A common feature shared by these two organelles is that alterations of mitochondrial and lysosomal enzymes usually lead to neurological pathologies, suggesting functional connections between mitochondria and lysosomes (Fraldi et al. 2016; Fivenson et al. 2017) . Many lysosomal storage diseases as a result of the mutation of lysosomal hydrolases show neurodegeneration as main clinical trait. Similarly, mitochondrial protein dysfunctions are often associated with neurological pathologies, such as Parkinson's disease (PD), Alzheimer's disease and dementia (AD), and amyotrophic lateral sclerosis (ALS). These mutations directly impair the structure and function of these organelles, leading to oxidative stress, accumulation of undigested intracellular material, and impaired cellular function. Notably, the role of intracellular organelles in neuropathophysiology represented an important topic at the 2017 International Society for Neurochemistry (ISN) meeting in Paris. In this review, we will describe not only the consolidated but also the most recent findings on the functional interaction between mitochondria and lysosomes in a neuropathological context. Specifically, we will focus on those diseases, such as PD, AD, and ALS, where the dysfunctional interaction between the two organelles seems to play a crucial role in the etiopathogenesis of the disease.
Pathways of mitochondria-lysosome interaction
Different pathways of communication between mitochondria and lysosomes have been described and include (i) mitophagy, transfer of (ii) mitochondria-derived vesicles (MDVs) and (iii) mitochondria-derived compartments (MDCs), and (iv) direct physical contact between mitochondria and lysosomes via membrane contact sits (Fig. 1 ).
Mitophagy represents a selective macroautophagy pathway which is especially important in post-mitotic cells, such as neurons, to remove dysfunctional mitochondria, which otherwise may result in toxic reactive oxygen species (ROS) production or trigger apoptosis. Mitophagy is induced by loss of the electrochemical mitochondrial membrane potential. During mitophagy damaged mitochondria are enclosed in a double membrane, building the autophagosome. Mitophagy pathways can be divided into ubiquitindependent and receptor-mediated mitophagy. Ubiquitindependent mitophagy utilizes the serine/threonine-protein kinase PTEN-induced putative kinase 1/parkin RBR E3 ubiquitin protein ligase (PINK1/PARKIN) system to ubiquitylate outer mitochondria membrane proteins which recruit adaptor proteins to initiate the engulfment of mitochondria via microtubule-associated protein 1 light chain 3-a (LC3) interaction on the phagophore membrane. In contrast, during receptor-mediated mitophagy outer mitochondrial membrane receptors are activated to increase their affinity to LC3, for example, by phosphorylation (BCL2-Interacting Protein 3 Like, BCL2-Interacting Protein 3 (BNIP3), and BCL2 Like 1 (BCL2L)) or other, so far unknown activators (Autophagy And Beclin 1 Regulator 1 and SMAD-Specific E3 Ubiquitin Protein Ligase 1 [for review see (Zimmermann and Reichert 2017) ].
Under physiological conditions, PINK1 is continuously internalized into mitochondria by outer mitochondrial membrane translocases (TOM) and inner mitochondrial membrane translocases. Within the mitochondria matrix, PINK1 is degraded by proteases, such as the mitochondrial processing peptidase and presenilin-associated rhomboid-like protease. However, in depolarized mitochondria, PINK1 accumulates at the mitochondrial surface. There, PINK1 stimulates the recruitment and activation of PARKIN by serine-65 phosphorylation of ubiquitin, which results in ubiquitination of mitochondrial surface proteins and recruitment of bidirectional autophagy adaptors such as nuclear dot protein 52, Sequestosome 1 (p62), neighbor of BRCA1 gene 1, tax1-binding protein, or optineurin that bind both, ubiquitin and autophagosomal membrane-associated protein LC3 (Geisler et al. 2010; Hollville et al. 2014; Heo et al. 2015; Moore and Holzbaur 2016) . In addition to surface ubiquitination, recruitment of autophagosomal membranes by interaction of the inner mitochondrial membrane protein prohibitin-2 (PHB2) seems to be required for mitophagy (Wei et al. 2017) . Outer mitochondria membrane rupture can be induced by PARKIN which recruits the proteasome, followed by proteasomal degradation of the outer mitochondria membrane and subsequent exposure of the inner mitochondria membrane protein prohibitin-2 (PHB2) (Yoshii et al. 2011) . PHB2 then links mitochondria to phagophore membranes by its LC3 interaction region.
Recently, PINK1 was shown to directly interact with beclin, a protein required for the nucleation of the phagophore membrane, to induce autophagy (Michiorri et al. 2010) . Interestingly, autophagosome formation is initiated at endoplasmic reticulum (ER)-mitochondria contact sites -'mitochondria-associated membranes' -(Hamasaki et al. 2013). Both, PINK1 and beclin localize to the mitochondria-associated membranes and enhance tethering as well as autophagosome formation (Gelmetti et al. 2017 ).
An alternative degradation pathway for ubiquitinated mitochondria utilizes the endosomal complex required for transport machinery for binding to RAB5A, member RAS oncogene family (RAB5) positive early endosomes. Inward Fig. 1 Different pathways of communication between mitochondria and lysosomes. Mitophagy, mitochondria-derived vesicles (MDVs), mitochondria-derived compartments (MDCs), and membrane contact site (MCS) are the main forms of functional interaction between mitochondria and lysosomes. Mitophagy starts with stressed and dysfunctional mitochondria (1). Impaired mitochondria lose membrane potential leading to PTEN-induced putative kinase 1 (PINK1) stabilization and then the formation of PINK1/parkin RBR E3 ubiquitin protein ligase (PARKIN)/Ubiquitin (Ub) complex and phagophore (2). This step is necessary to activate mitochondria digestion into lysosomes (3). MDCs differ from MDVs in respect to protein composition and function. MDVs are released in response to acute mitochondrial damage, while mitochondria-derived compartments (MDCs) have only been detected under chronic conditions, like aging. Damaged proteins and lipids are compartmentalized in a specific area of mitochondria (4) for subsequent ejection through the formation of little vesicles (5) intended to be digested in lysosomes (3). Finally, MCS represent the only known mechanism of physical interaction between mitochondria and lysosomes (6). This interaction allows the exchange of lipids and metabolites between these compartments (7).
budding of the endosomal-limiting membrane results in intraendosomal mitochondria (Hammerling et al. 2017) . These endosomes can later fuse with lysosomes for degradation of damaged mitochondria (Hwang et al. 2015) . Interference with this pathway was associated with increased cell death, supporting its important contribution to mitochondrial quality control (Hammerling et al. 2017) .
Surface-bound PINK1 and PARKIN can further impact mitophagy by association with the outer mitochondrial membrane protein Miro (Kane and Youle 2011) . Miro mediates mitochondria transport along microtubule through binding to Milton, an adaptor of kinesin heavy chain (Melkov et al. 2016) . In depolarized mitochondria, PINK1 and PARKIN associate with Miro, leading to its phosphorylation by PINK1 and subsequent proteasomal degradation. This pathway releases damaged mitochondria from microtubules, a process required prior to mitophagy.
In contrast to mitophagy which results in degradation of the whole organelle, mitochondria-derived vesicles (MDVs) serve to selectively remove only damaged proteins and lipids from otherwise intact, respiring mitochondria (Roberts et al. 2016) . A proportion of MDVs are targeted to peroxisomes; however, most MDVs is routed to lysosomes for subsequent degradation. Defective MDV formation may lead to dysfunctional mitochondria because of the accumulation of damaged mitochondrial proteins. MDVs bud directly from respiring mitochondria to the cytosol, both, at a steady-state level and induced by oxidative stress. MDV formation during oxidative stress is an early response mechanism. Similar to mitophagy, MDV budding relies on PINK1 and PARKIN, as mutations of these proteins are linked to reduced MDV formation (Vincow et al. 2013) . MDVs are still generated upon silencing of the mitochondrial GTPase dynamin related protein 1 which is required for mitochondrial fission, indicating that MDVs are not mitochondrial fragments (Soubannier et al. 2012) . MDV formation is also distinct from mitophagy, as silencing of autophagy protein 5, required for extension of the phagophore membrane and formation of LC3-II, has no impact on the generation of MDVs (Soubannier et al. 2012) . Furthermore, MDVs do not co-localize with LC3 (Soubannier et al. 2012) . So far, the mechanisms which target MDVs to lysosomes are still unknown, however, recent evidence indicated that direct interaction of MDVs with lysosomes relies on syntaxin 17, synaptosome-associated protein 29, vesicle-associated membrane protein 7, and the multisubunit tethering complex homotypic function and vacuole sorting (McLelland et al. 2016) . MDVs are positive for the outer mitochondria membrane protein TOM20. Interestingly, TOM20 immunoreactivity was found within both, the limiting membrane of multivesicular endosomes (MVE) and intraluminal vesicles which are generated by inward budding of the MVE membrane. Soubannier et al. described TOM20-positive vesicles budding from the MVE outer membrane into the MVE lumen (Soubannier et al. 2012) . MVEs can fuse either with lysosomes for degradation of their content or with the plasma membrane to release their intraluminal vesicles as exosomes to the extracellular space (Schneider and Simons 2013) . Interestingly, exosome preparations contain mitochondrial proteins and RNA. Thus, extracellular release of damaged mitochondrial proteins may serve as an alternative pathway to lysosomal degradation, especially in cells with low degradative capacities.
Mitochondria-derived compartments (MDCs) are vesicular structures released from mitochondria which carry selective cargo. MDCs were first described as a mechanism of selective protein degradation in yeast which relies on the sorting of damaged mitochondrial membrane compartments to the vacuole, an organelle similar to lysosomes in mammalian cells. MDC formation is triggered by cellular senescence and stress-related damage (Hughes et al. 2016) . In yeast, aging is associated with a loss of vacuolar pH control followed by reduced mitochondrial activity. Increased vacuolar pH could lead to impaired storage (Klionsky et al. 1990) , subsequently increased cytoplasmic amino acid levels and overflow of mitochondrial amino acid translocator proteins which mediate the import of amino acids into mitochondria (Hughes and Gottschling 2012) . It was suggested that MDC formation may serve to prevent overload of mitochondria with amino acids by release of mitochondrial membranes together with translocator proteins. Interestingly, nearly all mitochondrial outer membrane and a subclass of inner membrane carriers have been detected in MDCs. MDCs contain proteins imported into mitochondria by TOM70 but not TOM20, the majority being nutrient/ amino acid transporters across the inner mitochondrial membrane. TOM70 and TOM71 seem to be required for MDC formation as Tom70 knockout or double-knockout markedly reduce the formation of MDCs. However, it is not known how effective MDCs may be degraded within the vacuole of senescent cells with increased vacuolar pH and degradative impairment. Indeed, with increasing age, MDCs accumulated in the cytosol and failed to be delivered to the vacuole.
The MDCs are similar to MDVs as they serve as a mechanism to selectively remove membrane parts for subsequent degradation, while maintaining the mitochondrion. MDCs differ from MDVs in respect to protein composition and function. MDVs are released in response to acute mitochondrial damage, whereas MDCs have so far only been observed under chronic conditions, such as aging. Aging is linked to both, loss of vacuolar acidity and mitochondrial dysfunction. Supporting the notion that vacuolar dysfunction contributes to mitochondrial impairment, pharmacological inhibition of vacuolar-type H + -translocating ATPase in young yeast cells resulted in loss of mitochondrial membrane potential and induction of MDC formation as indicated by vacuolar TOM70 accumulation. Neither oxidative stress nor chemically induced mitochondrial depolarization was sufficient to trigger MDC release as assessed by vacuolar TOM70 degradation (Hughes et al. 2016) . Of note, MDCs differ from autophagosomes as they are still generated in autophagy-related protein 5-deficient cells but fail to fuse with the vacuole. In contrast to mitophagy, autophagyrelated protein 32 which serves as receptor for cargo sequestration by autophagosomes, is not a pre-requisite for MDC formation. It is not known whether MDCs exist also in mammalian cells and how they contribute to aging and neurodegeneration.
Similar to ER and mitochondria, membrane contact sites between mitochondria and lysosomes have been described in yeast and recently also mammalian cells (Wong et al. 2018) . The interaction between mitochondria and lysosomes allows the exchange of lipids and metabolites between these compartments (Elbaz-Alon et al. 2014; Honscher et al. 2014) . In yeast, mitochondria and the vacuole can transiently be connected by a protein-tethering complex termed 'vacuole and mitochondria patch requiring VPS39 homotypic function and vacuole sorting complex subunit (VPS39), vacuole and mitochondria patch (vCLAMP). This complex is enriched in ion and amino acid transporters and mediates phospholipid import into mitochondria, thus serving as a backup mechanism for phospholipid and potentially also calcium and iron exchange at the ERmitochondria encounter structure (Elbaz-Alon et al. 2014) . In addition, transient mitochondria-lysosome contacts were observed in mammalian cells. On average, contacts lasted for 10s and involved approximately 15% of all cellular lysosomes at a given time point (Wong et al. 2018) . Whether an exchange of metabolites occurs at mitochondria-lysosome contact sites is not clear, although imaging analysis ruled out bulk transfer between both organelles. Importantly, mitochondria at lysosomal contact sites were negative for autophagosomal markers and therefore distinct from mitophagosomes. The interaction between mitochondria and lysosomes is modulated by the endolysosomal small GTPase RAB7, member RAS oncogene family (RAB7) which not only promotes contact but also prolongs contact duration. Upon GTP hydrolysis by the RAB7-TBC1D15 GTPase-activating protein-TBC1 domain family, member 15 (TBC1D15) complex, mitochondria and lysosomes contact sites become untethered. TBC1D15 is recruited to mitochondria by the mitochondrial fission protein 1 (FIS1). TBC1D15-mediated inactivation of lysosomal RAB7 at mitochondria-lysosome contact sites may negatively affect lysosomal function, including transport, maturation, and fusion. Thus, mitochondria could modulate key lysosomal functions. In return, lysosomes may regulate mitochondrial fission by FIS1. Wong et al. provide evidence that membrane contact sites with lysosomes mark the positions where later mitochondrial fission occurs, in a process similar to mitochondria ER contact sites in yeast (Friedman et al. 2011 ). There, ER contact promotes constriction of the mitochondria prior to the recruitment of fission factors (Murley et al. 2013 ). It will be interesting to study the impact of aged or dysfunctional lysosomes in neurodegenerative diseases on mitochondrial fission.
Molecular interaction between mitochondria and lysosomes
Originally known as Parkinson's disease-associated proteins, PINK1 and PARKIN have been associated with mitochondrial function for the first time through studies in Drosophila M. (Park et al. 2006) . Nowadays, we know that PINK1 and PARKIN are required for the proper function of both lysosomes and mitochondria (Ivankovic et al. 2016) . Upstream signaling or mitochondrial damages activate mitophagy pathway, leading to PINK1 accumulation on the outer mitochondrial membrane as a tag to amplify the signal. PINK1 is constantly imported into mitochondria and degraded by the inner mitochondrial membrane-associated presenilin-associated rhomboid-like protease, and loss of mitochondrial membrane potential leads to PINK1 stabilization and accumulation by unknown mechanisms (Meissner et al. 2015) . Then, by the action of the E3 ubiquitin ligase PARKIN, mitochondria are marked for either proteasomal or autophagic degradation (Tait and Green 2012) . In this second pathway, lysosomes enclose mitochondria in an isolation membrane, leading to fusion of organelle membranes and final protein degradation (McWilliams and Muqit 2017) . In addition, acute and chronic mitochondrial dysfunction activate a stress signaling pathway that regulates lysosomal biogenesis via the microphthalmia transcription factor family (Fern andez-Mosquera et al. 2017) . Notably, the effect of mitochondrial impairment on lysosomal biogenesis depends on the timeframe of the stress elicited. Respiratory chain inhibition with rotenone or uncoupling through carbonyl cyanide m-chlorophenyl hydrazone initially triggers lysosomal biogenesis, peaking after few hours. After few hours the induction returns to baseline. On the other hand, long-term respiratory chain inhibition or mutations in patient fibroblasts and in a mouse model leads to repression of lysosomal biogenesis. The induction of lysosomal biogenesis by PINK1 and acute mitochondrial stress is dependent on transcription factor EB (TFEB) translocation to the nucleus following mitophagy induction. TFEB is the master regulator for transcription of genes involved in autophagy and lysosome biogenesis. Its accumulation in the nucleus increases mRNA expression of TFEB itself and lysosomal proteins, such as glucocerebrosidase and cathepsin D (CTSD). Further results indicate that PARKIN Q311X mutation alters mitochondrial quality control via TBC1 domain family, member 2 (TBC1D1/PARIS)-mediated regulation of peroxisome proliferator-activated receptor gamma coactivator 1-a (the master regulator of mitochondrial biogenesis)-TFEB signaling (Siddiqui et al. 2015) . PARKIN Q311X mutation detrimental effects are because of inhibition at the level of downstream lysosomal function. Nevertheless, rapamycin restores PGC-1a-TFEB pathway, suggesting a relevant role of mammalian target of rapamycin (mTOR) in the regulation of mito-lysosomal homeostasis. This kinase belongs to the mTOR complex 1 (mTORC1), which controls not only cell proliferation, differentiation, and autophagy but also mitochondrial function (Morita et al. 2015; Saxton and Sabatini 2017) . In fact, mTOR activation also leads to senescence regression caused by oxidative stress as a result of mitochondrial and lysosomal dysfunction in neurons (Tai et al. 2017) . mTOR coordinates energy metabolism by regulating the synthesis of nuclear-encoded mitochondrialrelated proteins, including transcription factor A mitochondria, mitochondrial ribosomal proteins and some subunit of complexes I and V. Active mTORC1 is usually localized on lysosomes and has been reported to disassociate from the lysosomal surface in the absence of amino acids. Moreover, mTORC1 activity has been linked to the vacuolar H + -ATPases (V-ATPases), responsible for lysosomal acidification. Nevertheless, the exact function of the V-ATPases in mTORC1 signaling is still poorly understood. Recent evidence indicates that mTORC1 and V-ATPases cooperate to regulate amino acid efflux from lysosomes, and that this function might be relevant for preventing the inappropriate consume of essential amino acids during starvation and energy consumption, a state in which lysosomal and proteasomal activity are a major source of amino acids (Abu-Remaileh et al. 2017) . Further proofs clearly indicate that ubiquitin-proteasome pathway directly participates in autophagy and lysosomal function by controlling TFEB activity (Sha et al. 2017) . STIP1 homology and U-Box containing protein 1 is a chaperone-dependent E3 ubiquitin ligase that regulates TFEB activity by preferentially degrading inactive phosphorylated TFEB. Youbao S. et al. also demonstrated that mTOR-mediated TFEB phosphorylation along with inactive STIP1 homology and UBox containing protein 1 results in reduced autophagy and impaired mitochondrial biogenesis. Altogether, these findings suggest a possible role of mTOR-TFEB axis in the regulation of molecular mechanisms that tune mitochondrial and lysosomal function in pathological contexts. In the next paragraphs, we will describe the main findings about the association of these molecular mechanisms with the onset of PD, AD, and ALS.
Mitochondria, lysosomes, and Parkinson's disease
Parkinson's disease (PD) is a long-term neurodegenerative disorder that affected 6.2 million people and led to 117,400 deaths globally in 2015 (Vos et al. 2016) . The mechanistic etiopathogenesis of PD is currently unknown, even though we know that the disease is characterized by the degeneration of the substantia nigra (SN) dopaminergic neurons. Nevertheless, recent results disclosed the role of a number of proteins as putative contributors to the onset of PD. Neuronal health relies on efficient lysosomal function and optimal delivery of proteins and organelles by autophagy for following degradation. Increasing number of experimental evidence indicates that mitophagy, the specific degradation of mitochondria, is required not only for proper fertilization and development but also for the correct intracellular homeostasis throughout life and aging (Palikaras and Tavernarakis 2012; Rojansky et al. 2016; Song et al. 2016 ; Esteban-Mart ınez et al. 2017). As described above, one of the most important pathways associated with sporadic and hereditary early PD onset is the PINK1/PARKIN axis. Drosophila M. PINK1 mutants fail to maintain normal synaptic transmission and show defects in reserve pool function (Morais et al. 2009 ). These animals also show impaired mitochondrial function, with specific defects in complex I activity. In mammal cells, under abundant nutrient conditions or after physical exercise, damaged and depolarized mitochondria are selectively degraded mainly through the PINK1/PARKIN pathway (McWilliams and Muqit 2017). Recent researches focused their attention on the characterization of PINK1 and PARKIN1 regulators or autophagy effectors. By a genome-wide Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 highthroughput screening, Potting C. and colleagues identified THAP Domain Containing 11 (THAP) as negative regulator of PARKIN intracellular abundance (Potting et al. 2017) . Transcriptomic analysis demonstrated that PARKIN-encoding locus as a prime THAP domain containing 11 (THAP11) target, and THAP11 deletion in several cell types enhanced pUb accumulation. On the other hand, RAB guanine nucleotide exchange factor (GEF) 1 has been recently identified as an important downstream effector of PINK1/ PARKIN-activated cascade (Yamano et al. 2018) . RAB-GEF1, the upstream factor of the endosomal RAB GTPase pathway, is recruited to dysfunctional mitochondria via ubiquitin binding. Subsequent recruitment of RAB5 and RAB7 induces in turn autophagy-related 9A-mediated vesicle assembly and formation of autophagosome. The role of RAB5 in PARKIN-mediated mitochondrial clearance was further demonstrated by Gustafsson A. B. group (Hammerling et al. 2017) . Particularly, they reported that the autophagy factor Beclin1 boosts activation of RAB5 and endosomal-mediated degradation of mitochondria, suggesting cross talk between these two pathways. Also RAB7 has been recently demonstrated to mediate mitochondrial-lysosomal contacts allowing bidirectional regulation of mitochondrial and lysosomal dynamics (Wong et al. 2018 ). RAB7 GTPase cycles from an active GTP-bound state into an inactive GDP-bound state upon GTP hydrolysis. Contact establishment is enhanced by active GTP-bound lysosomal RAB7, and contact releasing is facilitated by recruitment of RAB7 GTPase-activating protein TBC1D15 to mitochondria by mitochondrial FIS1. This interaction drives RAB7 GTP hydrolysis and thereby untethers contacts. Contact sites are extremely important for lysosomal-mediated mitochondrial fission, while mitochondrial contacts regulate lysosomal RAB7 hydrolysis via TBC1D15. These data may contribute to explain why lysosomal and mitochondrial pathologies show similar clinical manifestations and why concomitant dysfunction in both organelles is present in several human diseases.
As a central regulator of cell metabolism, autophagy, and cell survival, mTOR represents a potential target in PD therapeutic approach, even though clinical approaches based on its modulation are still unavailable. Furthermore, the evidences about a possible mTOR-protective role in neurodegenerative disorders are rather contradictive. Recent findings indicate that miR-124 down-regulation significantly boosts cell apoptosis and induces autophagy-associated protein expression in an in vitro model of PD (Gong et al. 2016) . miR-124 suppression increased the phosphorylation levels of the energy sensor AMP-activated protein kinase (AMPK) but decreased p-mTOR levels, protecting dopaminergic neurons during PD through the involvement of cell apoptosis and autophagy. Similar results were obtained with miR-185 (Wen et al. 2016 ). 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated SH-SY5Y dopaminergic neurons show decreased levels of miR-185, whose overexpression significantly reduced the MPTP-induced apoptosis. In addition, the expression levels of the autophagy markers Beclin 1, LC3I/II, p-AMPK and p-mTOR, were significantly up-regulated in MPTP-treated SH-SY5Y cells but down-regulated in miR-185 over-expressing cells, which also show decreased apoptosis induction. Furthermore, PD toxins have been demonstrated to inhibit mTOR-mediated ribosomal protein S6 kinase B1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) pathways, leading to neuron death (Xu et al. 2014) . On the other hand, the inhibition of mTOR signaling contributes to neuronal cell death and is attributed to the AKT Serine/ Threonine kinase 1 (AKT) suppression and activation of AMPK kinase. Furthermore, ectopic expression of AKT or dominant negative AMPKa partially rescues the phosphorylation of mTOR, S6K1, and 4E-BP1, preventing apoptosis through caspase-3 inhibition and hampering neuronal cell death. Notably, metformin (an activator of AMPK) prevents dopaminergic neuron death in MPTP-induced mouse model of PD via autophagy and mitochondrial ROS clearance . In addition, NADPH oxidase (NOX2) promotes parkinsonian phenotypes by altering autophagic flux in an mTORC1-independent fashion in a cellular model of PD (Pal et al. 2016) . Specifically, rotenone treatment of SHSY-5Y cells for a short time increased NOX2-ROS generation and impaired autophagic flux in an mTORC1/AMPK-independent fashion by up-regulating Rous sarcoma oncogene (SRC)/phosphatidylinositol-4,5-bisphosphate 3-kinase/AKTmediated phosphorylation of Beclin1 at S295 and concomitant disruption of Beclin1-phosphatidylinositol 3-kinase catalytic subunit type 3 complex. The exposure to a higher concentration of rotenone for longer duration induced even further ROS generation leading to lower lysosomal acidification, lysosomal activity, and autophagic flux. Notably, inhibition of NOX2-dependent oxidative stress rescues homeostasis of autophagic flux. These data clearly suggest the presence of some mTOR-independent regulatory circuitries of autophagy in neurons. These mTOR-independent pathways should be further explored to spread the therapeutic possibilities for PD. In this context, TFEB seems to hold a key spot in the regulation of PD progress. In fact, genetic (TFEB over-expression) and pharmacological induction of autophagy protect SN dopaminergic neurons from a-synuclein (a-SYN) over-expression (Decressac et al. 2013; Kilpatrick et al. 2015) .
Kufor-Rakeb syndrome is an autosomal recessive form of PD associated with dementia caused by mutations of the Ptype ATPase-type 13A2 (ATP13A2/PARK9) (Ramirez et al. 2006 ). Kong and coworkers demonstrated that endogenous human ATP13A2 is a key protein to maintain zinc levels in multivesicular bodies, thus potentially promoting the biogenesis of a-SYN-enriched exosomes. Indeed, the authors nicely reported that increased ATP13A2 expression favored a-SYN intracellular removal via exosomes while lower expression of ATP13A2 led to a-SYN intracellular accumulation (Kong et al. 2014) . Alterations of ATP13A2 impair lysosomal functions, reduce lysosomal acidification hence degradation of substrates and lead to accumulation of fragmented mitochondria. ATP13A2 bears a N-terminal hydrophobic extension that lies on the cytosolic leaflet of the lysosome, where it interacts with the lysosomal signaling lipids phosphatidic acid (PA) and phosphatidylinositol (3,5) bisphosphate (PI(3,5)P2). ATP13A2 builds up in an inactive autophosphorylated state induced by PA and PI(3,5)P2. Holemans T. et al. demonstrated that only catalytically active ATP13A2 protects the cell against rotenone-induced mitochondrial stress in a cellular model of PD, showing that this mechanism relies on the bioavailability of PA and PI(3,5)P2. Hence, the activation of prosurvival ATP13A2 by lysosomal fatty acids may offer a futurist therapeutic strategy for PD and its complications (Holemans et al. 2015) . Another report directly links ATP13A2 to mTORC1 and TFEB pathway, highlighting the great importance of this protein in the pathological scenario of PD (Bento et al. 2016 ). The authors demonstrate that ATP13A2 and synaptotagmin 11, a PD-associated gene, form a new functional pathway in the control of the autophagylysosome network. Specifically, ATP13A2 down-regulation negatively impacts synaptotagmin 11 at both transcriptional and post-translational levels, which induces lysosomal dysfunction, autophagy blockage, and increased accumulation of PD-associated A53T a-SYN.
Another pathway linked to PD onset is represented by the two proteins vacuolar protein sorting-associated protein 35 (VPS35) and eukaryotic translation initiation factor 4 gamma 1 (Dhungel et al. 2015) . Specifically, Dhungel N. et al. identified a functional interaction between VPS35, eukaryotic translation initiation factor 4 gamma 1, and a-SYN.
Increasing evidences implicate PD-associated proteins, such as a-SYN and leucine-rich repeat kinase 2 (LRRK2), in mitochondrial dysfunction in genetic cases of PD. In mammalian brain, a-SYN localizes at the pre-synaptic terminal and regulates synaptic vesicle recycling and docking (Marques and Outeiro 2012) . a-SYN fibrils, raised by specific single nucleotide polymorphisms (SNPs), are the main constituent of Lewy Bodies, while a-SYN aggregates lead to neuronal death (Ingelsson 2016) . Furthermore, impaired autophagy was shown to be associated with a-SYN accumulation, amplifying the accumulation of altered mitochondria (Devoto et al. 2017) . Mutations of the large kinase LRRK2, which also have GTPase activity, are responsible for almost 40% of genetic cases of PD and the predominant cause of autosomal-dominant PD. Orenstein and colleagues demonstrated that LRRK2 is degraded in lysosomes by chaperone-mediated autophagy (CMA), whereas this pathway was almost ineffective on G2019S, the most common pathogenic mutant form of LRRK2. In contrast to other CMA substrates, LRRK2 represents a substrate for which binding to the lysosomal membrane is potentiated by other CMA substrates, leading to an impaired CMA translocation complex at the lysosomal membrane. This resulted in increased levels of lysosome-associated membrane protein 2A, a hallmark found in the brain of Parkinson's disease patients with the LRRK2 mutation. The authors conclude that LRRK2-mediated blockage of lysosome-associated membrane protein 2A multimerization favored to accumulation of other CMA substrates, such as a-SYN, at the surface of the lysosomal membrane by increasing the time that substrate proteins remain bound to the membrane before translocation, thus contributing to neuronal a-SYN accumulation (Orenstein et al. 2013 ). In addition, LRRK2 takes part in different pathways and interacts with many proteins in the endolysosomal compartment, like the Rab-family proteins. LRRK2 might not only be crucial for autophagosome formation but also for the maturation and/or the lysosomes trafficking regulatory pathway. Strikingly, LRRK2 mutations associated with PD impairs mitochondrial morphology by altering the activity of dynamin-like protein 1, which controls mitochondrial fusion/ fission events (Wang et al. 2012) . Remarkably, dynamin-like protein 1-mediated defects in mitochondrial morphology were also observed in association with VPS35 mutations, revealing a new pathogenic molecular mechanism of familial and sporadic PD involving VPS35 and mitochondrial dynamics (Wang et al. 2016b) . The retromer complex is a multimeric protein complex involved in recycling proteins from endosomes to the trans-Golgi network (TGN) or plasma membrane. The cation-independent mannose 6-phosphate receptor mediates sorting of lysosomal hydrolase precursors from the TGN to endosomes. After releasing the hydrolase precursors into the endosomal lumen, the unoccupied receptor returns to the TGN for further rounds of sorting. Arighi and coworkers demonstrated that VPS35 is part of the retromer complex by interacting with the cytosolic domain of the cation-independent mannose 6-phosphate receptor and play a key role in sorting cargo proteins (i.e., cathepsin D) in lysosome (Arighi et al. 2004) . Another study suggested that dysfunctional LRRK2 reduces mitochondrial membrane potential and ATP production (Papkovskaia et al. 2012) , which could be associated with the impaired mitochondrial dynamics described above. Zavodszky E. et al. also reported that VPS35 D620N mutation leads to a rare form of autosomal-dominant Parkinson's disease (PD) (Zavodszky et al. 2014) . Particularly, D620N VPS35 has a low affinity for the WASH complex, impairing its recruitment to endosomes and leading to dysfunctional autophagy pathway. This autophagy defect is a contributor to PD pathogenesis, as it would worsen many of the defects associated with the disease, such as protein aggregation and mitochondrial abnormalities. This last hypothesis was experimentally confirmed by a mouse model where Vps35 was selectively removed from dopamine neurons resulting in PD-like deficits, including loss of dopaminergic neurons and a-SYN accumulation (Tang et al. 2015) . In addition, mitochondria appeared fragmented and dysfunctional in Vps35-KO dopaminergic neurons, while mitochondrial E3 ubiquitin ligase 1 was up-regulated in the same cells, thereby leading to mitofusin-2 degradation and up-regulated mitochondrial fission. Furthermore, Vps35 depletion in Drosophila M. boosts the lysosomal turnover of the mannose 6-phosphate receptor, thus affecting the trafficking of the lysosome protease CTSD, responsible for a-SYN degradation. Vps35 knockdown perturbed the maturation of CTSD and led to a-SYN buildup in the lysosomes. Moreover, the authors demonstrate that Vps35 loss leads to locomotor damages, mild compound eye disorganization, and interommatidial bristle loss in flies over-expressing human a-SYN. Taken together, these reports indicate that VPS35 represent a direct link between mitochondrial dynamics, lysosome function, and PD onset.
The Deglycase Parkinson disease (autosomal recessive, early onset) 7 (DJ-1/PARK7) has been recently found to be associated with PD onset. DJ-1 loss-of-function mutations lead to an aggressive and early onset form of autosomal PD (Burbulla et al. 2017) . Specifically, mitochondrial oxidant stress in dopaminergic neurons of human substantia nigra pars compacta caused by DJ-1 deficiency activates a dopamine-dependent toxic cascade that in turn leads to lysosomal dysfunction and a-SYN accumulation. Krebiehl G. et al. also demonstrated that E64D mutation of DJ-1 impaired mitochondrial respiration, increased intramitochondrial reactive oxygen species, decreased mitochondrial membrane potential, and altered mitochondrial shape. Notably, ultrastructural imaging and lysosomal activity analyses revealed also impaired autophagic degradation and hence the buildup of defective mitochondria in DJ-1 mutant cells (Krebiehl et al. 2010) . Similar effects were also found in transmembrane protein 175 (TMEM175)-deficient rat primary neurons (Jinn et al. 2017) . TMEM175 is a lysosomal K + channel centered under a genome-wide association studies peak for PD. TMEM175-deficient cells show unstable lysosomal pH, impaired lysosomal catalytic activity, decreased glucocerebrosidase activity, altered autophagosome clearance by the lysosome, and decreased mitochondrial respiration. Moreover, TMEM175 deficiency lead to increased susceptibility to exogenous a-SYN fibrils and increased phosphorylated and detergent-insoluble a-SYN deposits. Taken together, these findings contribute to causally link three major pathological features of PD, namely mitochondrial dysfunction, lysosomal dysregulation, and a-SYN buildup, raising the possibility of a direct pathogenic positive feedback between the two organelles. Future efforts must be focused on the identification of therapeutic approaches for PD able to properly tune mitochondrial and lysosomal activity in pathological conditions.
Mitochondria and lysosomal storage disorders
Lysosomal storage diseases (LSDs) consist of 50 rare inherited disorders that are because of specific defects in lysosomal function. Specifically, LSDs result from the lack of a single enzyme essential for the metabolism of lipids, glycoproteins (sugar-containing proteins), or mucopolysaccharides (Aronovich and Hackett 2015; Parenti et al. 2015) . Separately, LSDs arise with incidences of < 1: 100 000. Usually, these disorders are autosomal recessively inherited, such as Niemann-Pick disease, type C (Torres et al. 2017a ). Only few LSDs are X-linked recessively inherited, like Fabry disease and Hunter syndrome (Echevarria et al. 2016; Demydchuk et al. 2017) . Most of the times, LSDs affect children that die at a very young and random age, and despite being multisystemic disorders, most of them display neurological symptoms and neurodegeneration. From a molecular point of view, LSDs are usually classified on the nature of accumulated products (i.e., sphingolipids, gangliosides, mucopolysaccharides, and glycoproteins), and only recently the role of mitochondria in their pathophysiology has come to the surface (Plotegher and Duchen 2017) . The Neuronal Ceroid Lipofuscinoses (NCL) are the most common cause of neurodegeneration among children and are classified as LSDs. These disorders are characterized by blindness, seizures, progressive cognitive defects, and motor failure. NCL, commonly referred to as Batten disease, includes a family of disorders caused by mutations in the ceroid lipofuscinosis (CLN) genes. Nowadays, 14 different mutations in CLN genes have been identified that are classified into infantile, late infantile, juvenile (not considered typical LSD since it is not associated with a lysosomal enzyme deficiency), and adult-onset forms. Late infantile NCL is caused by mutations in CLN2, a lysosomal enzyme (tripeptidyl peptidase I, TPP1), that cleaves tripeptides from the terminal amine groups of partially unfolded proteins. In NCL, the accumulation of dysfunctional mitochondria, increased expression of LC3-II, and the down-regulation of the mTOR pathway are typically detected (Onyenwoke R.U. and Brenman J.E. J Exp Neurosci. 2015; 9 (Suppl 2): 81-91, 2016). Neuronal and astrocyte mitochondria of a neuropathic Gaucher's disease mouse model show small dimensions and fragmented network (Osellame et al. 2013) . Similar results were obtained in fibroblasts derived from Gaucher's disease patients (de La Mata et al. 2015) . Niemann-Pick type C disease is another overwhelming lysosomal-lipid storage disease featured by hepatosplenomegaly, progressive neurological impairment, and early death. At the moment, no valuable cure for this disorder is available. Neuroblastoma SH-SY5Y and oligodendroglial MO3.13 transiently transfected with Npc1 small interfering RNA display impaired mitochondrial function together with a significant accumulation of cholesterol (Ferrante et al. 2016) . The authors also demonstrated that stimulation of adenosine A2A receptors diminishes intracellular cholesterol levels and rescues mitochondrial abnormalities in both neurons and oligodendrocytes. Buildup of cholesterol seems to directly impair also mitochondrial GSH import, leading to mitochondrial GSH depletion (Torres et al. 2017b) . In addition, the authors show that GSH ethyl ester (GSH-EE), but not N-acetylcysteine, rescues the mitochondrial GSH pool in both liver and brain of Npc1 À/À mice and in fibroblasts from NPC patients. GSH-EE also improved the median survival and maximal life span of Npc1 À/À mice, while intraperitoneal injections with GSH-EE protect against oxidative stress and cell death and reverse locomotor defects in Npc1 À/À mice. GSH-EE enhanced oxidative phosphorylation, coupled respiration, and maximal electron transfer in cerebellum of Npc1 À/À mice as well.
Mitochondrial function was significantly reduced also in brains and cultured astrocytes from b-galactosidase (b-gal) À/À mice, a preclinical model of G M1 -gangliosidosis (Takamura et al. 2008) . G M1 -gangliosidosis is an autosomal recessive LSDs, caused by mutations of the lysosomal b-GAL and is characterized by the accumulation of G M1 . b-gal À/À astrocytes-isolated mitochondria are morphologically abnormal and show decreased membrane potential and b-gal À/À astrocytes are extremely sensitive to oxidative stress. Collapsing and electrondense mitochondria are also present in the brain of hexosaminidase subunit b (Hexb) knockout mice, a model of GM2 gangliosidosis . Furthermore, neurons from a mouse model of mucopolysaccaridosis III type C show swollen and damaged mitochondria (Martins et al. 2015) . In these cells, the expression levels of complexes II and IV of oxidative phosphorylation are reduced, as well as the levels of coenzyme Q. Recent findings clearly suggest a mitochondrial dysfunction also in neuronal ceroid lipofuscinosis preclinical models and patients (Wavre-Shapton et al. 2015; Uusi-Rauva et al. 2017) . Retinal degeneration and visual impairment are the first signs of juvenile neuronal ceroid lipofuscinosis caused by ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) (CLN3) mutations, followed by inevitable progression to blindness (Hall et al. 1991; Palmer et al. 1992; Luiro et al. 2006) . Cln3 Dex1À6 null mice show lysosomes containing mitochondrial F 0 -ATP synthase subunit c along with undigested membranes, suggesting decreased degradative capacity. Likewise, the ceroid lipofuscinosis, neuronal 5 (CLN5) Y392X neural cells derived from human-iPSC display accumulation of excessive storage material and subunit C of the mitochondrial ATPase, both hallmarks of many forms of NCLs, including CLN5 disorder. Palmitoyl-protein thioesterase 1 (CLN1) and ceroid lipofuscinosis, neuronal 6 (CLN6) mutations lead to similar results (Pezzini et al. 2011) . Mitochondria from CLN1-and CLN6-mutated cells are fragmented and mainly localized at the cell periphery, with the voltage-dependent anion channel and oxidative phosphorylation complex IV up-regulated expression levels, consistent with accumulation of degenerated mitochondria. Other research lines identified diverse mitochondrial defects in mouse and human models of Pompe disease as well (Lim et al. 2015) , Pompe disease is a life-threatening cardiac and skeletal muscle myopathy: Pompe muscle cells show a deep dysregulation of Ca 2+ homeostasis leading to mitochondrial Ca 2+ overload together with increased reactive oxygen species and altered mitochondrial membrane potential, which finally results in decreased oxygen consumption and ATP production. Despite this information, the specific molecular mechanisms that lead to neurodegeneration in LSDs still remain obscure. It is clear that mitochondria are strongly associated with LSDs, however, a big effort still must be done. Specifically, it will be critical to understand different aspects of mitochondrial biology in LSDs (i) to identify the main mechanism(s) that ends in mitochondrial dysregulation, (ii) whether altered mitochondria contributes to clinical signs of the disease, and (iii) if the rescue of mitochondrial function is a valuable therapeutic approach for these disorders.
Mitochondria, lysosomes, and Alzheimer's disease
Cell stress can promote misfolding and aggregation of proteins which, in the case of many neurodegenerative diseases, confer toxicity, and result in cellular dysfunction and death. Pathological protein aggregates in AD are composed of the microtubule-associated protein tau and amyloid-b peptides cleaved from the amyloid precursor protein (APP). To counteract toxic protein aggregation, various clearance pathways can be up-regulated, such as increased proteasomal activity, autophagy, release of toxic proteins by extracellular vesicles, and lysosomal degradation (Kunadt et al. 2015; Stuendl et al. 2016; Wang et al. 2017 ) (Gadhave et al. 2016) . The transcription factor TFEB can induce the increased generation of lysosomes in early AD stages to oppose pathological protein aggregation and accumulation. However, a progressive loss of lysosomal activity is observed during disease progression, as reflected by enlarged lysosomes and decreased activity of lysosomal hydrolases, including cathepsin D (Nixon 2017) . Decreased lysosomal capacities further promote accumulation of toxic protein aggregates and subsequent cell death. Lysosomal dysfunction in AD is caused by age-related impairment and loss of lysosomal acidity, overload with aggregated proteins, and rupture of endolysosomal membranes [reviewed in (Nixon 2017) ]. Endolysosome rupture was observed following the endocytic uptake of fibrillar aggregates of a-SYN, TAU, and Huntingtin (Flavin et al. 2017) . Ruptured lysosomes undergo autophagy by exposure of otherwise intraluminal galectins 8 and 3 (Papadopoulos et al. 2017) . Lysosomal membrane permeabilization not only results in the reduction of the lysosomal pool and overload of the autophagy system but also in the release of cathepsins and other lysosomal hydrolases to the cytosol which contributes to cell death.
In addition to clearance of aggregated proteins by the endolysosomal/autophagic system, a mitochondrial degradation pathway has been described in yeast and mammalian cells (Ruan et al. 2017) . Mitochondrial proteostasis can be up-regulated in response to increased protein aggregation, lysosomal overload, and impairment. In yeast, aggregated proteins bind to the mitochondria surface and can be imported into mitochondria by the outer mitochondrial membrane transporters TOM70 and 40 after chaperone HSP104-mediated disaggregation. Within the mitochondrial matrix, disassembled protein aggregates are degraded by proviral integration site 1. This process of mitochondriamediated proteostasis was termed 'mitochondria as guardian in cytosol', requires an intact mitochondrial membrane potential, and may thus be compromised by mitochondrial dysfunction. The study by Ruan et al. (2017) investigated mitochondrial degradation of proteins induced to aggregate by heat shock. It is still not known whether this pathway is also involved in mitochondrial proteostasis of AD-related tau and amyloid-b aggregates. Interestingly, TOMM40, the gene which encodes for TOM40 translocator protein, lies adjacent to ApoE and was repeatedly discussed as a potential risk factor for sporadic AD (Roses et al. 2010) .
It is tempting to speculate that the mitochondrial import of aggregation-prone, disease-linked proteins may confer toxic effects on mitochondria, either by overloading their degradative capacities or by interference with their bioenergetics function (Ruan et al. 2017) . The failure to degrade amyloid-b further fuels its toxic effects on mitochondria, namely respiratory chain dysfunction (Veereshwarayya et al. 2006; Liang et al. 2008) , generation of oxidative stress, and ultimately apoptosis. Mitochondria toxic effects of amyloidb are mediated by either direct interaction or inhibition of complex 1, indirect effects on complex IV by increased ROS production, and by permeabilization of mitochondrial membranes through oligomeric amyloid-b (Sanz-Blasco et al. 2008; Bobba et al. 2013) . Of note, intramitochondrial amyloid-b accumulation has been described in App transgenic AD mice and human AD brains (Du et al. 2010; Cha et al. 2012) . Amyloid-b can either be imported in mitochondria by outer membrane translocases (TOM) (Hansson Petersen et al. 2008) , mitochondrial receptors for advanced glycation end-products (Takuma et al. 2009 ), or locally cleaved from APP by mitochondrial c-secretase (Behbahani et al. 2010; Pavlov et al. 2011) . Intramitochondrial amyloidb is degraded by pitrilysin metallopeptidase 1 (PREP). PREP activity is decreased in AD brains and AD mouse models (Alikhani et al. 2011) , which is associated with increased oxidative stress. Importantly, activation of mitochondrial amyloid-b clearance by increased neuronal expression of PREP in an AD mouse model ameliorated oxidative stress, neuroinflammation, and improved synaptic function, learning, and memory (Fang et al. 2015) .
The analysis of mitochondrial gene expression levels in AD and prodromal AD patient' brains revealed a striking mitochondrial stress response signature, suggestive of decreased oxidative phosphorylation and mitochondria import together with an up-regulation of mitophagy and mitochondrial unfolded protein response (UPRmt) (Sorrentino et al. 2017) . This signature was also detected in transgenic mouse and worm AD models, suggesting a conserved pathway. UPRmt is triggered by the accumulation of misfolded and aggregated proteins within mitochondria and was suggested to play a protective role in AD. UPRmt serves to maintain or re-establish intramitochondrial protein homeostasis by induction of transcription factors which enhance the expression of chaperones and proteostasisrelated genes. The activation of either UPRmt or mitophagy increased life span in a C.elegans AD model. In a transgenic AD mice, activation of both UPRmt and mitophagy pathways by nicotinamide riboside, improved mitochondrial and cognitive function and reduced amyloid plaque load (Sorrentino et al. 2017) . Thus, mitochondria fulfill an important function in maintaining proteostasis in AD.
Mitochondria, lysosomes, and amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a debilitating pathology whose cause is unknown in 90-95% of new cases. The hereditary form (5-10% of cases) is inherited in an autosomal-dominant manner and the most common mutations are found in the superoxide dismutase 1 (SOD1) gene. Nevertheless, mutations of C9orf72 have been also associated with hereditary form of ALS. When no cause is known, the most plausible hypotheses for ALS onset, even though still not experimentally confirmed, are head injury, alcohol, and smoke exposure. The first SOD1 polymorphism associated with familial ALS was found in 1993 (Rosen et al. 1993) . Thus, in the last decades, researchers have focused their interest mainly on the characterization of mitochondrial pathways involved in ALS development. Nevertheless, in the last few years, increasing evidence highlighted the contribution of lysosomes/autophagy to the onset and progression of the disease (Deng et al. 2017; Sullivan et al. 2017) . In support of this notion, it has been demonstrated that mTOR activation, along with excitability, is somehow associated with ALS delay and extended survival, while TFEB expression is decreased in the human brain of AD and ALS patients, supporting the involvement of autophagy in ALS (Saxena et al. 2013; Wang et al. 2016a) . On the other hand, TFEB hyper-translocation to the nucleus was observed in TAR DNA-binding protein 43 (TDP-43)-deleted SH-SY5Y neurons (Xia et al. 2015) . ubiquitinated, (the pathologic form of TDP43) is the principal disease protein found in ubiquitin-positive, tau-, and a-SYNnegative frontotemporal dementia and ALS. However, loss of TDP-43 alters the fusion of autophagosomes with lysosomes by dynactin-1 down-regulation, inducing the buildup of immature autophagic vesicles and altering the autophagy-lysosome pathway function. Importantly, inhibition of mTORC1 signaling by rapamycin accelerates the neurodegenerative phenotype in a Tdp-43-depleted Drosophila model. Wang et al. (2018) also demonstrated that TFEB itself is able to control TDP-43 levels in trehalosetreated cells. Beyond mTOR, TFEB, and TDP-43, recent works have demonstrated the association of a number of proteins with ALS. Among these, ALS-associated mutant ubiquilin-2 (UBQLN2) sequesters ubiquitinated proteins from protein degradation system, thus leading to alteration of proteasomal and autophagic activity in Neuro2A cells (Osaka et al. 2016) . Moreover, results of a sequencing study aimed at identifying new genes that contribute to predisposition for ALS, revealed that the gene TANKbinding kinase 1 (TBK1) is associated with the pathology (Cirulli et al. 2015) . Particularly, TBK1 binds to and phosphorylates several proteins involved in innate immunity and autophagy, including optineurin and SQSTM1/sequestosome, both already implicated in ALS. Recently, it has been also described that familial ALS patients display a missense mutation in SIGMAR1 (SIG-1R) (c.304G>C), causing a substitution of glutamic acid at amino acid residue 102 with a glutamine (p.E102Q) (Fukunaga et al. 
2015). Expression of the mutant SIG-1R
E102Q protein impairs mitochondrial ATP production and inhibits proteasomal activity leading to death in Neuro2A cells. On the other hand, in literature there are also reports which demonstrate the positive effects of autophagy induction in ALS. Notably, the mTOR-independent autophagic enhancer trehalose extends motor neuron survival and increase the autophagic flux in vitro and in a mouse model of ALS, while selective inhibition of Src/c-Abl kinases boosts autophagy and rescues ALS motor neurons from degeneration Imamura et al. 2017) . Furthermore, mTOR inhibition by rapamycin increases motor neurons degeneration in SOD1 G93A mouse model of ALS, while resveratrol delayed ALS onset and extended the lifespan when given to the same mouse model (Zhang et al. 2011; Song et al. 2014) . Specifically, resveratrol treatment increases sirtuin 1 (SIRT1) expression levels, diminishes motor neuron loss, ameliorates muscle atrophy, and improves mitochondrial activity in muscle fibers of ALS mice. Conversely, rilmenidine treatment boosts mTOR-independent autophagy without improving disease phenotype, while rapamycin treatment increases survival in ALS mice (Staats et al. 2013; Perera et al. 2017) . In light of these notions, we can make some considerations about the role of autophagy in ALS onset and treatment: in the future, it will be crucial (i) to unveil weather dysregulation of autophagy and lysosomal degradation of protein aggregates is a trigger of sporadic forms of ALS, (ii) to comprehend weather an autophagy-based pharmacological treatment represents a valuable option for ALS cure, and (iii) to characterize the molecular peculiarities of mitochondria-autophagosome relationship in ALS. Given the mitochondrial nature of SOD1 and C9orf72 forms of familial ALS, this last aspect is of great importance; in fact, the understanding of mitochondria/autophagosome dynamics in familial ALS will increase our possibilities to slow down, or even revert, the progress of the disease.
Conclusions
In the last years, our understanding of organelle physiology opened new research areas focused on their functional and physical interactions. In this context, mitochondria and lysosomes have been demonstrated to cooperate and interact to regulate key intracellular metabolic features (Fig. 1) . In support of this notion, several studies demonstrated that the alteration of key players of mitochondrialysosome interaction leads to onset of neurological diseases (Table 1) . Nevertheless, our knowledge about the molecular mechanisms governing mitochondria-lysosome cooperation is far from complete. Specifically, new studies must focus on (i) the characterization of the molecular function of the known players, (ii) dissecting their role in both recognized and unrecognized pathologies, and (iii) the identification of new regulators of lysosomal and mitochondrial function. Given the great importance of mitochondria and lysosomes in cell physiology and pathology onset, particularly in neurodegenerative disorders, these are important question to which we must find an answer.
